Merck presents RWE study of multiple sclerosis drug Mavenclad in Koreans < Pharma < Article

Merck Biopharma Korea released the results of a real-world evidence (RWE) study of Mavenclad (cladribine) for multiple sclerosis (MS) in Korean patients at the 40th European Committee for Treatment...

Multiple sclerosis drug pipeline

There are several ways for pharmaceuticals for treating multiple sclerosis (MS) to reach the market. Novel pharmaceuticals cannot enter the US market without FDA approval, which typically requires evidence of safety and efficacy in human trials and large fees be submitted to the FDA and fo...

New multiple sclerosis drug Ocrevus is approved in Korea - dailypharmkorea

Ho Jin Kim, Professor of Neurology, the National Cancer Center A new drug for multiple sclerosis (MS), an intractable disease characterized by a high relapse rate, has been introduced to...

Sanofi’s Multiple Sclerosis Drug Slows Disease’s Progression - Bloomberg

Sanofi’s experimental drug for a form of multiple sclerosis delayed the progression of disability by nearly a third, providing hope for patients for whom there’s currently no treatment.

Tysabri Treatment for Multiple Sclerosis

Tysabri is a drug used to treat multiple sclerosis (MS). WebMD explains how it works.

FDA Approves First Biosimilar to Treat Multiple Sclerosis | FDA

FDA has approved the first biosimilar to Tysabri (natalizumab) injection for the treatment of relapsing forms of multiple sclerosis.

Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for D....

PALM BEACH, Fla., June 11, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - In the last twenty years, the amount of people with multiple sclerosis (MS) in the United States has more than doubled. In 2000, it was estimated by the National Multiple Sclerosis Society that around 400,000 Americans had the disease. In 2017, that estimate had jumped to 900,000. Although estimates between studies differ, it’s commonly accepted that about 800,000-900,000 individuals in the United States suffer from MS, out of a global population of 2-3 milli ...

FDA approves new oral drug to treat multiple sclerosis | FDA

The U.S. Food and Drug Administration today approved Mayzent (siponimod) tablets to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-...

Multiple Sclerosis Drug Shows Promise as New Alzheimer’s Therapy - Neuroscience

A groundbreaking revealed that ponesimod, a drug originally used to treat multiple sclerosis, shows potential in treating Alzheimer’s disease.

FDA approves new oral treatment for multiple sclerosis | FDA

FDA approves Mayzent (cladribine), a new oral drug to treat multiple sclerosis